Dr Rosanna Campitiello
Country: Italy
Rosanna is a rheumatologist and PhD candidate in Clinical and Experimental Immunology at the University of Genova, Italy, where she works at the Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology. Her major research interests are systemic sclerosis, rheumatoid arthritis, innate immunology in connective tissue disease, and nailfold videocapillaroscopy
Rosanna is a member of the EMEUNET Education Sub-Committee
| Poster 0503| Sunday, 08.11.2026 10:30–12:30 Session: Poster Session A: Rheumatoid Arthritis – Diagnosis, Manifestations, & Outcomes Presenting author: A. Phothisane (USA) Title: Respiratory infections and ILD progression account for more than 60% of deaths in RA-ILD: results from a multicenter cause-specific mortality analysis  In this retrospective multicenter study, deceased RA-ILD patients were identified through electronic records from three French tertiary referral centers (2009-2026). The leading primary causes of death were infections (34.8%, mostly respiratory, including 9 COVID-19 deaths) and ILD progression or acute exacerbation (31.5%). ILD was directly or indirectly involved in 60.9% of deaths. Patients with FVC <80% at diagnosis more often died of ILD-related causes (48.7% vs 18.2%; p=0.005), whereas cardiovascular deaths prevailed when lung function was preserved (18.2% vs 2.6%; p=0.032). |
| Oral 1834| Monday, 09.11.2026 08:30 Session: Rheumatoid Arthritis – Diagnosis, Manifestations, & Outcomes: Preclinical RA Presenting author: A. Di Matteo (United Kingdom) Title: Ultrasound-detected bone erosions during the preclinical phase identify a severe disease trajectory in CCP+ individuals following inflammatory arthritis development. In the Leeds CCP cohort, 193 CCP+ at-risk individuals who progressed to inflammatory arthritis (IA) were analysed. Pre-IA ultrasound erosions were found in 37.3% (most often at the fifth MTP), whereas radiographic erosions were present in only 5/72 (6.9%) of the ultrasound-erosion-positive subgroup. These progressors had higher b/tsDMARD use (50.7% vs 31.9%; p=0.013) and more difficult-to-treat disease (15.5% vs 6.0%; p=0.042). The number of erosions predicted radiographic damage. Preclinical ultrasound erosions may identify a severe disease trajectory. |
| Oral 1836| Monday, 09.11.2026 09:00 Session: Rheumatoid Arthritis – Diagnosis, Manifestations, & Outcomes: Preclinical RA Presenting author: L. Duquenne (United Kingdom) Title: Catching the window for interception in individuals at risk of developing inflammatory arthritis: design of a dynamic “Imminent Risk Score” In 543 anti-CCP+ individuals with musculoskeletal symptoms, of whom 176 (32.4%) progressed to inflammatory arthritis, a dynamic “Imminent Risk Score” applicable at any visit was developed. Four features predicted progression within 6 months: anti-CCP ≥3x ULN, elevated RF, morning stiffness ≥30 minutes and ≥1 small tender joint. Discrimination was comparable to the previously published Baseline Risk Score (C-index 0.864 vs 0.856). When all four features were present, specificity reached 86.3% (positive predictive value 46.2%): nearly 1 in 2 individuals progressed within 6 months. The score may help select candidates for interception trials. |
| Poster 1444| Monday, 09.11.2026 10:30–12:30 Session: Poster Session B: Rheumatoid Arthritis – Diagnosis, Manifestations, & Outcomes Presenting author: G. McDermott (USA) Title: Genes and genetic variants associated with non-response to multiple targeted therapies in rheumatoid arthritis: an analysis using whole genome sequencing data. Whole genome sequencing was performed in 243 RA patients: 157 non-responders to multiple b/tsDMARDs from the RANT study, 105 of them treatment-refractory, and 86 TNFi responders as controls. Three variants reached genome-wide significance for association with the number of b/tsDMARDs used, and one gene (RBM38-AS1) was associated at gene level (FDR <0.10). No variant or gene distinguished treatment-refractory patients from TNFi responders. External validation is needed. |
| Poster 1436| Monday, 09.11.2026 10:30–12:30 Session: Rheumatoid Arthritis – Diagnosis, Manifestations, & Outcomes Poster B Presenting author: T. O’Malley (USA) Title: Convergent Temporal, Clinical, and Geographic Evidence for Association Between Borrelia and Anti-RA33 Immune Response Identified by Analysis of 148,839 Patients In 148,839 multi-analyte autoimmune panel orders, anti-RA33 IgG positivity (emerging biomarker for RA) showed a seasonal pattern, peaking in May (12.4%) and falling in December (6.9%) (warm vs cold months OR 1.40, 95% CI 1.35-1.45). Anti-CCP and SLE markers did not vary by season. The seasonal effect was stronger in states with high Lyme incidence (median OR 1.50 vs 1.35; p=0.016), and anti-RA33 IgM tended to be higher in Lyme-coded patients (OR 2.03; p=0.052). Anti-RA33 IgG should be interpreted taking Lyme exposure into account. |
| Poster 1430| Monday, 09.11.2026 10:30–12:30 Session: Poster Session B: Rheumatoid Arthritis – Diagnosis, Manifestations, & Outcomes Presenting author: I. Usiskin (USA) Title: Association Between GlycA and Vascular Inflammation in Rheumatoid Arthritis: Secondary Analysis of the TARGET Randomized Trial Comparing TNF Inhibition With Triple Therapy In a secondary analysis of the TARGET trial, 111 RA patients with inadequate response to methotrexate were treated with triple therapy or a TNF inhibitor for 24 weeks. Arterial inflammation was measured by FDG-PET/CT at baseline and at 24 weeks. Reduction in GlycA, a composite inflammatory biomarker, correlated with reduction in arterial inflammation, independently of hsCRP (β=0.14; p=0.047). In conclusion, GlycA may reflect changes in vascular inflammation in RA. |